Aclarion, Inc.
As of Oct 22, 2026, Aclarion is in Stage 4, the downtrend phase, now in week 18 (since Jun 17, 2026). It closed at $1.94, 76.3% below its 52-week high and below its 200-day average, which is falling.
Aclarion, Inc. operates as a healthcare technology company in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is ACON early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ACON among Health Information Services35th of 41 by relative strength
All 41 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | AMWL | Stage 2 · wk 25 | 97 | +7.4% |
| 2 | HNGE | Stage 2 · wk 20 | 96 | +19.1% |
| 3 | BTSG | Stage 3 · wk 8 | 94 | +9.1% |
| 4 | NRC | Stage 3 · wk 4 | 93 | −0.1% |
| 5 | SOPH | Stage 2 · wk 24 | 91 | −12.7% |
| 6 | HTFL | Stage 2 · wk 10 | 87 | +17.0% |
| 7 | HSTM | Stage 2 · wk 17 | 77 | +20.3% |
| 8 | OMCL | Stage 4 · wk 10 | 70 | +12.5% |
| …35 | ACON | Stage 4 · wk 18 | 13 | −34.2% |
Aclarion: quick answers
What stage is Aclarion in?
As of Oct 22, 2026, Aclarion (ACON) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 17, 2026 and is in week 18. What the four stages mean
Is Aclarion in an uptrend?
No. Aclarion is in a Stage 4 downtrend. It trades 34.5% below its 200-day average, which is falling.
How far is Aclarion from its 52-week high?
Aclarion closed at $1.94 on Oct 22, 2026, 76.3% below its 52-week high of $8.17. Its 52-week low is $1.85.
How has Aclarion performed over the past year?
As of Oct 22, 2026, Aclarion is down 75.3% over the past year and down 61.1% so far in 2026.
Which sector and industry is Aclarion in?
Aclarion is in the Health Information Services industry, part of the Health Care sector.
About this companyHealth Care· Health Information Services
Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.